Since the presence of Chlamydia nucleic acids has been shown in synovial fluid (SF) from some patients with Chlamydia reactive arthritis, we investigated whether commercially available tests, developed to detect Chlamydia nucleic acids in urogenital samples, could also be used for their detection in SF samples. We therefore tested SF samples, found positive with at least two different systems of DNA amplification in a previous study, with three commercially available kits. No positive results were obtained. It is concluded that the commercially available tests Gen-Probe PACE 2, Amplicor (developed by Roche Molecular Systems) and LCx (developed by Abbott Laboratories) do not have sufficient sensitivity to detect reliably Chlamydia RNA or DNA in SF.
S it has been shown that chlamydial rRNA and DNA are present in synovial fluid (SF) and tissue [1] [2] [3] [4] of some patients with reactive arthritis and undifferentiated seronegative oligoarthropathies, it could be tempting to use the different commercially available kits, developed to detect Chlamydia nucleic acids in urogenital samples, to look for Chlamydia nucleic acids in SF samples. These tests are much easier to perform than nested polymerase chain reaction (PCR) followed by gel electrophoresis, blotting and hybridization.
The first kit developed was a DNA-RNA hybridization system with a chemiluminescent-labelled, singlestranded DNA probe complementary to the Chlamydia trachomatis rRNA (PACE 2 developed by Gen-Probe). Later, a PCR test (Amplicor, developed by Roche Molecular Systems) became available, using a single set of biotinylated oligonucleotide primers directed against a 207 bp fragment of the C. trachomatis plasmid. Biotinylated amplicons are detected colorimetrically after specific hybridization with an immobilized oligonucleotide capture probe bound to the bottom of wells of a 96 microwell plate [5] . The last one is a ligase chain reaction (LCR)-based assay (LCx, developed by Abbott Laboratories). This uses two complementary pairs of probes targeted at a 48 bp fragment of the plasmid, which, when the correct template is available, hybridize next to each other. Polymerase acts to fill in the gap and then ligase can covalently join the pair of probes. Amplified products are detected with a microparticle sandwich immunoassay based on covalent labelling of the four probes with two different immunoreactive chemical groups [6] . These tests are aimed at use with urogenital samples, and the PCRand LCR-based assays with urine samples as well. The last two give excellent specificity and sensitivity when compared to culture and antigen detection [6, 7] .
PATIENTS AND METHODS

Patients
Thirteen to 16 SF samples found positive with at least two different systems of DNA amplification and 5-23 samples found negative in a previous study [1] were used to evaluate the commercially available tests.
Quantitation of Chlamydia trachomatis elementary bodies (EB)
A dilution panel of C. trachomatis serovar D (American Type Culture Collection, Rockville, MD, USA) was prepared from stock grown in McCoy cells. A fluorescein isothiocyanate (FITC)-conjugated monoclonal antibody (MicroTrak, Syva, Palo Alto, CA, USA) was added as specified in the manufacturer's instructions. The FITC-antibody-stained EB were counted by epifluorescent microscopy.
Treatment of samples
SF pellets were prepared from aliquots of 1 ml as previously described [1] . Aliquots of 100 ml were also prepared for each sample at the time of collection of the SF and stored at −80°C until used.
Detection of Chlamydia trachomatis rRNA by Gen-Probe PACE 2 system (Gen-Probe Inc., San Diego, CA, USA) SF pellets and 100 ml aliquots were thawed, set into Gen-Probe transport tubes and vortexed to ensure suspension in the transport medium. They were otherwise processed according to the instructions of the kit manufacturer. 
Detection of Chlamydia trachomatis plasmid DNA by Amplicor (Roche Molecular Systems, Basel, Switzerland)
Different experimental conditions were tested. SF pellets and 100 ml aliquots were either treated with hyaluronidase and proteinase K as previously described [1] , or processed as urine samples according to the manufacturer's instructions.
Detection of Chlamydia trachomatis plasmid DNA by LCx (Abbott Laboratories, North Chicago, IL, USA)
Different experimental conditions were tested. Hundred microlitre aliquots of SF were either diluted 1/2 or 1/10 (with or without proteinase K treatment [1] for dilution 1/2). After heating to 97°C for 15 min, 100 ml of the mixture were used for the amplification procedure.
Statistics
Differences between groups were estimated using the two-tail t-test (Student).
RESULTS
Sensitivity of the Gen-Probe PACE 2 system
A positive result was always obtained when 10 000 EB were added to four different pellets prepared from 1 ml of control SF (2.4 × 10 5 -6.2 × 10 7 cells) ( Fig. 1 ). However, as mentioned previously, the dissolution of the SF pellets was not always complete. With 100 ml aliquots, a positive result (close to the (Table I) .
Sensitivity of the Amplicor system
When SF pellets were mixed with 1.25 ml of urine resuspension buffer and 1.25 ml of urine diluent, no dissolution was observed, except for one of the 34 pellets tested. This pellet contained the lowest number of SF cells (5 × 10 4 ) and a positive result was obtained when 20 EB were added.
However, since these experimental conditions did not allow the majority of the pellets to be dissolved, other experimental conditions were tested. With samples previously found positive [1] , the highest optical density values were obtained when 100 ml aliquots of SF were mixed with 100 ml of urine resuspension buffer and 100 ml of urine diluent. In these conditions, 1000 EB were added to five different SF preparations and one positive result was obtained for one sample containing 0.03 × 10 5 cells (in the test) (Table II) .
Sensitivity of the LCx system
With samples previously found positive [1] , the highest rates of fluorescence were obtained when aliquots of SF were mixed with an equal volume of urine specimen resuspension buffer. In these conditions, 60 EB were added to five different SF preparations and two positive results were obtained for the samples containing 0.01 × 10 6 and 1.1 × 10 6 cells (in the test) (Table III) .
Comparison of the sensitivities of the different systems to detect Chlamydia trachomatis nucleic acids in SF
The sensitivities varied from 20 EB/ml with nested PCR targeting plasmid sequences [1] to 100 000 EB/ml of SF with the Gen-Probe PACE 2 system. The best sensitivity of the commercially available tests was obtained with the LCx system (1200 EB/ml of SF) ( Table IV) .
Detection of Chlamydia trachomatis rRNA and plasmid DNA by commercially available tests in SF samples
SF samples previously found positive with at least two different systems of DNA amplification [1] and SF samples previously found negative were tested. No positive results were obtained according to the instructions of the kit manufacturers and the values obtained for samples previously found positive were not significantly different from those obtained for samples previously found negative (Tables I-III) .
With the Gen-Probe PACE 2 system, three SF aliquots of 100 ml previously found positive and 12 previously found negative were also tested and found negative. For the commercially available PCR system (Amplicor), processing the specimens after heat treatment to 95°C and centrifugation decreased the values for both groups of samples.
DISCUSSION
Three commercially available tests, developed to detect Chlamydia nucleic acids in urogenital samples, were tested with SF samples. We performed the assays either directly on SF pellets (with Gen-Probe PACE 2 and Amplicor) or on 100 ml aliquots, without nucleic acid extraction, in order to minimize sample handling and to see whether these kits could be used in a very simple way to detect Chlamydia nucleic acids in SF specimens. However, it is important to be aware that the sensitivity of these tests depends largely on the specimen processing. To be used with good chances of success, it is necessary to test a large amount of a sample, but this requirement is contraindicated with the presence of Taq polymerase in two of these kits. Indeed, this enzyme is sensitive to inhibitors present in SF samples and will be less inhibited if the specimens are more diluted. The 'ideal' experimental conditions are a balance between these two requirements.
The use of SF pellets could be an advantage since it allows a larger number of cells to be tested without inhibitor products susceptible to being present in SF. The comparison of the sensitivities obtained for the SF pellets and the 100 ml aliquots was performed with the Gen-Probe PACE 2 system and with Amplicor. For both systems, the best sensitivity is obtained with SF pellets. However, their use is limited by the difficulty of dissolving them and, if the pellets are not completely dissolved, it is difficult to assume an efficient detection of nucleic acids.
The sensitivity of the kits was tested by adding increasing amounts of C. trachomatis EB to SF samples before processing. With Amplicor, a sensitivity of 20 EB was obtained when a non-inflammatory SF containing 5 × 10 4 cells/ml was used. However, it was not possible to test the other samples in the same experimental conditions since they were not dissolved. In conditions allowing the processing of all the samples, the best sensitivity of the three commercially available tests varied from 2000 (Gen-Probe PACE 2) to 60 EB (LCx), corresponding to 100 000 (Gen-Probe PACE 2) to 1200 EB (LCx) per millilitre of SF.
For the Gen-Probe PACE 2 system, we obtained a higher sensitivity than Kuipers et al. [8] who reported a sensitivity of 1 × 10 6 EB/ml of SF. This discrepancy could be explained by differences in the specimen processing or by the number of cells present in the samples. Indeed, our results show that the higher the number of cells, the lower the sensitivity of this system.
For the PCR and LCR systems, the sensitivities also depended on the samples and not only on the cell number. The presence of more amplification inhibitors in some particular SF could explain the variable sensitivities observed.
Samples previously found positive with at least two different systems of DNA amplification [1] were tested with these commercially available tests and no positive results were obtained. This could be explained by the insensitivity of these tests. Indeed, the DNA amplification systems developed by Bas et al. [1] had a sensitivity between 1 and 50 EB (present in the test). However, the LCx system had a sensitivity close to 50 EB for 2/5 samples. It could be possible to find positive results in samples without a strong inhibition effect or in synovial tissue samples since Branigan et al. [9] found that chlamydial DNA is more reliably identified in tissues than in SF. It is also important to be aware of the difficulty of determining the sensitivity of these assays, the DNA template coming from added EB is probably not comparable in quality and quantity to the DNA coming from SF samples.
For each test, we compared the means obtained for samples previously found positive with the means obtained for samples previously found negative in order to see whether a difference could be observed in spite of the fact that the values were lower than the cut-off. No significant differences were observed.
In conclusion, in our experimental conditions, the commercially available kits Gen-Probe PACE 2, Amplicor and LCx cannot be reliably used to detect Chlamydia RNA or DNA in SF.
